Biomarker ID | 500 |
PMID | 20028763 |
Year | 2009 |
Biomarker | Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed |
Biomarker Basis | Expression Based |
Biomolecule | DNA (Gene) |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) |
Type of Biomarker | Prognostic |
Cohort | All patients had clinical stage pT3 or pT2C. 30 patients were selected who expreienced biochemical reccurance within 1 y of RP and/or had positive lymph nodes identified at the time of surgery. Controls were selcted (n=24) such that they remained disease free for 24 months. |
Senstivity | 43% |
Specificity | 75% |
AUC | NA |
Accuracy | 57% |
Level Of Significance | NA |
Method Used | Array comparative genomic hybridization. |
Clinical | No |
Remarks | 39 BAC-based markers of metastasis to assess recurrence risk in silico for high-risk radical prostatectomy cases. This set of biomarkers, the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP). FIXED: A fixed threshold of 2.5 times the sample median absolute deviation, as defined above, was applied to the log2 ratio values to determine gain/loss status of each probe. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |